Healthcare
Septerna, Inc.(SEPN)
Live Price
Offline$36.17
+1.03% today
1Y Change
+243.49%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.06B
- Revenue Growth
- +4174.5%
- EPS Growth
- +84.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Septerna, Inc. (SEPN) is a Healthcare stock with a market cap of $1.06B and listed on NASDAQ. The stock last traded around $36.17 and up 243.5% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +4174.5%, EPS growth of +84.8%, a dividend yield of 0.0%. What stands out right now is revenue +4174.5%, EPS +84.8%, free cash flow +257.6% with operating margin -148.6% and ROIC -13.4%. Valuation already assumes a fairly strong business story at price/sales 23.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SEPN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+4174.5% vs +7.6% peer median
Operating Margin
Below sector median
-148.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4174.5% and EPS at +84.8%, with operating margin around -148.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +1.6% | +8.2% | โ |
2026 Mar 9, 2026 | -4.3% | -3.6% | -13.5% | -14.5% |
2025 Nov 10, 2025 | -147.4% | +6.3% | +19.6% | +40.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SEPN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SEPN Max Drawdown
-25.18%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SEPN and SPY.
Company Overview
Septerna, Inc.
NASDAQ Global Select
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
- Leadership
- Jeffrey T. Finer
- IPO Date
- Oct 25, 2024
- Employees
- 75
- Street Address
- 250 East Grand Avenue
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 338 3533
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 23.1
- Price/Book
- 2.7
Growth
- Revenue
- +4174.5%
- EPS
- +84.8%
- Free Cash Flow
- +257.6%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -148.6%
- Net Margin
- -106.4%
- ROE
- -12.6%
- ROIC
- -13.4%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 4.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.